机构：[1]Department of Ophthalmology & Clinical Center of Optometry, Peking University People's Hospital, Beijing 100044, China.[2]Eye Diseases and Optometry Institute, Peking University People's Hospital, Beijing 100044, China.[3]Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, Beijing 100044, China.[4]College of Optometry, Peking University Health Science Center, Beijing 100191, China.
To explore the process of retinal vascularization and risk factors for retinopathy of prematurity (ROP) treated with intravitreal ranibizumab (IVR) as monotherapy.Infants with type 1 ROP who received IVR as primary treatment from August 2014 to October 2016 at Peking University People's Hospital's Ophthalmology Department were included in the study. All eyes received 0.25 mg ranibizumab at initial treatment. Retinal vascularization was evaluated clinically. Potential risk factors were also recorded and examined.Retinal vascularization was completed in 126 eyes (62.7%), and retinal vascularization terminated in zone II and zone III with 16 eyes (7.9%) and 44 eyes (21.9%), respectively, after more than 1-year follow-up. In multivariate regression analysis, lower birth weight (BW), severity of ROP and repeated injections were found to be risk factors for peripheral avascular area (P<0.05).In our retrospective study, 29.8% of the ROP eyes treated with ranibizumab have peripheral avascular area at the last follow-up. Lighter BW and the severity of ROP are risk factors. Furthermore, repeated injections also increase the risk of retinal peripheral avascular area remaining in ROP patients.
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2018]版：
大类|4 区医学
小类|4 区眼科学
最新[2023]版：
大类|4 区医学
小类|4 区眼科学
第一作者：
第一作者机构：[1]Department of Ophthalmology & Clinical Center of Optometry, Peking University People's Hospital, Beijing 100044, China.[2]Eye Diseases and Optometry Institute, Peking University People's Hospital, Beijing 100044, China.[3]Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, Beijing 100044, China.[4]College of Optometry, Peking University Health Science Center, Beijing 100191, China.
共同第一作者：
通讯作者：
通讯机构：[1]Department of Ophthalmology & Clinical Center of Optometry, Peking University People's Hospital, Beijing 100044, China.[2]Eye Diseases and Optometry Institute, Peking University People's Hospital, Beijing 100044, China.[3]Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, Beijing 100044, China.[4]College of Optometry, Peking University Health Science Center, Beijing 100191, China.[*1]Department of Ophthalmology, Peking University People's Hospital, Xizhimen South Street 11, Xi Cheng District, Beijing 100044, China
推荐引用方式(GB/T 7714)：
Meng Qing-Yu,Cheng Yong,Zhao Ming-Wei,et al.The process of retinal vascularization in retinopathy of prematurity after ranibizumab treatment in China.[J].International Journal of Ophthalmology.2019,12(7):1146-1150.doi:10.18240/ijo.2019.07.15.
APA：
Meng Qing-Yu,Cheng Yong,Zhao Ming-Wei&Liang Jian-Hong.(2019).The process of retinal vascularization in retinopathy of prematurity after ranibizumab treatment in China..International Journal of Ophthalmology,12,(7)
MLA：
Meng Qing-Yu,et al."The process of retinal vascularization in retinopathy of prematurity after ranibizumab treatment in China.".International Journal of Ophthalmology 12..7(2019):1146-1150
